Provider review
New Wave Health review: it tells you who it is, then moves the trial results a year early
New Wave Health does the thing most of this market won't. It tells you who it is — a company name, a Virginia Beach street address, dated terms, and a postal address for opting out of arbitration. Then it tells you what to expect, and moves the evidence forward by about a year. Its semaglutide page puts a 15% average loss at month six; the trial that produced that average ran 68 weeks. Its tirzepatide page puts 20% at month six and adds that "many members exceed this range"; that trial ran 72 weeks. On price, it publishes only floors — plans "from $139/mo", confirmed after a provider reviews you — beside a promise of "transparent pricing".
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit New Wave HealthOf New Wave Health’s 7 dated product claims documented below, 0 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Publishes its company, its address and its terms — then puts the trials' 68- and 72-week results at month six, and quotes only a floor price.
Worth trusting if
- You want a company you can identify, write to and serve papers on, which this one publishes
- You want the plain statement that compounded medicines are not FDA-approved, which it gives
Be skeptical if
- You want to know what it costs before handing over your address, because the site publishes only floors
- You are planning around a trial average at month six, which the trials took well over a year to reach
- You want to know which pharmacy fills the prescription or which clinician writes it
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at New Wave Health
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — No price on the page. The site's figures are all floors: its peptide catalog lists semaglutide injection "from $139/mo", and the homepage says plans start from $139 a month, "confirmed after provider review".
- Compounded tirzepatide injection — No price on the page, which promises flat-rate pricing. The site's peptide catalog lists tirzepatide injection "from $149/mo", and the homepage says plans start from $139 a month, "confirmed after provider review".
- GLP-1 Microdose
- NAD+ — No price on the product page. The site's peptide catalog lists NAD+ "from $199/mo", a floor rather than a quoted rate.
- Tesamorelin — The peptide catalog lists tesamorelin "from $299/mo", the highest floor on the peptide menu. The product page itself shows no price.
- Sermorelin — The peptide catalog lists sermorelin "from $249/mo". The product page itself shows no price.
- PT-141 — The peptide catalog lists PT-141 "from $249/mo". The product page itself shows no price.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
4
Products with human evidence
For the advertised use, out of 7 products reviewed here. The evidence concerns the molecule, not New Wave Health's service.
6
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from New Wave Health’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
About the tesamorelin
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“Semaglutide. The foundational GLP-1 program — refined dosing, managed by your dedicated provider, delivered to your door with flat-rate pricing and no hidden fees. CLINICAL AVERAGE ~15% body weight. […] Realistic timelines drawn from published clinical trials and the patients we work with. Individual response varies — the curve is consistent. […] MONTH 6 ~15% Average body weight reduction reported in published trials.”
Read on the New Wave Health site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. Reported a mean weight reduction of about 15% — at 68 weeks, not at 24.
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg tirzepatide. Its roughly 20% mean is the highest published for an approved medicine in this class, and it took 72 weeks.
The figure is right and the date is wrong. STEP 1 reported a mean loss of about 15% on semaglutide — after 68 weeks, not at month six. Placing that average at month six promises the trial's full result in roughly a third of the time it took, and calling the timeline "realistic" and "drawn from published clinical trials" is where it fails: no published semaglutide average has that shape. The homepage chart makes the same move from the other side, labeling a 15.2% loss at week 24 a "typical trial milestone", while its own footnote concedes the trials ran "roughly 24–72 weeks". "Flat-rate pricing and no hidden fees" sits on a page that states no rate.1,2
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim reaches past the trials
“Tirzepatide. A dual-agonist GLP-1 / GIP program designed for patients seeking advanced metabolic results under provider direction with flat-rate pricing. CLINICAL AVERAGE ~20% body weight. […] Highest average weight loss recorded in published GLP-1-class trials. […] MONTH 6 ~20% Average body weight reduction in published trials. Many members exceed this range.”
Read on the New Wave Health site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 20% at the top dose.
Two of these three claims hold. SURMOUNT-1's roughly 20% mean at the top dose is the highest published for an approved medicine in this class, so "highest average weight loss recorded" is fair, and ~20% is the trial's figure. The third moves it: SURMOUNT-1 reached that average after 72 weeks, and the page places it at month six, then adds that "many members exceed this range" — a claim about its own patients that no published figure backs. The trial also used the branded drug; this is a compounded preparation no randomized trial has tested.2
GLP-1 MicrodoseGLP-1 (molecule not named) · Compounded (503A)No trial supports this claim
“GLP-1 Microdose. A lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite recalibration — not aggressive weight loss. […] Many of GLP-1's positive effects on metabolism, inflammation, and appetite signaling are preserved at lower doses.”
Read on the New Wave Health site, September 2026
No trial for this use
No trial can be matched to this product because New Wave Health never says what is in it. Read in September 2026 across its own site — the homepage, all three treatment pages and the terms — and, on September 13, 2026, across all twenty-eight screens of the signup: the homepage lists the product as "LOW-DOSE · 500 MCG/ML", a concentration, and no page names the molecule. A trial record cannot be attached to an unnamed drug, and guessing which one it is would be inventing the evidence base.
A product described by its dose relative to an unnamed drug, credited with keeping "many of GLP-1's positive effects" at a lower dose. Even with the molecule named that would sit outside the published evidence: STEP 1 and SURMOUNT-1 both titrated participants up to a maintenance dose and measured them there, so a deliberately reduced dose is a different treatment rather than a cheaper share of the same one, and neither trial measured body composition or inflammation as its outcome. Unnamed, there is nothing to weigh at all.
NAD+NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+. Not a peptide but a coenzyme your cells run on — NAD+ replenishes the electron-carrying fuel that quietly thins as the decades add up. […] Replenishes an age-depleted coenzyme central to energy metabolism. May support steadier day-long physical and mental energy. Studied for its role in mitochondrial function and cellular repair signaling.”
Read on the New Wave Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
The page is candid about what NAD+ is — "not a peptide", a coenzyme — and most of its science section describes biochemistry and research interest rather than results. The offer is the part that reaches: "replenishes an age-depleted coenzyme" and "may support steadier day-long physical and mental energy" describe outcomes no completed randomized trial of injected NAD+ in people has measured. "Studied for its role" is true of the molecule in the laboratory, and a buyer could easily read it as studied in patients like them, which it has not been.3
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“The stabilized GHRH analog studied specifically for the deep abdominal fat that resists diet and training. […] Studied for deep visceral fat, not just surface weight. Aims to support a leaner waistline and body composition. […] It is a compounded medication prescribed only if a licensed provider deems it appropriate for you.”
Read on the New Wave Health site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
"Studied specifically for the deep abdominal fat" is true, and the page never says in whom. Tesamorelin's two phase 3 trials, 675 participants, measured visceral fat in people with HIV-associated lipodystrophy, which is how it came to be approved as Egrifta. The page sells it to adults whose belly fat "resists diet and training" and never mentions HIV. The larger problem is the product itself. The page calls it "a compounded medication", and tesamorelin has been regulated as a biologic since March 23, 2020, which leaves a pharmacy no lawful route to compound it. What is on offer is not a version of the approved drug the trials tested.5,6
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“A GHRH analog that asks your own pituitary to release growth hormone on its natural nightly schedule — rather than replacing the hormone from outside. […] Sermorelin is most often used to support restorative rest, recovery, and the sense of vitality that can soften with age. […] May support recovery, body composition, and daytime energy over a course of use.”
Read on the New Wave Health site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery, sleep, body composition or energy as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
The first sentence is the tested part: sermorelin prompts the pituitary to release its own growth hormone, and that is what all 19 randomized trials measured. The rest is what the product is sold for, restorative rest, recovery, body composition and daytime energy, and none of those was an outcome in any of them. The page moves from one to the other without marking where the evidence stops.4
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“The peptide that starts in the brain rather than the bloodstream — PT-141 is studied for the melanocortin pathways tied to sexual desire, in women and men alike. […] Explored for low libido in both women and men. Used as-needed before intimacy rather than dosed daily.”
Read on the New Wave Health site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
The women's half of "in women and men alike" rests on 1,437 participants across two phase 3 trials, which is why an approved version of bremelanotide exists. The men's half rests on nothing in that record: the RECONNECT trials enrolled premenopausal women with hypoactive sexual desire disorder and nobody else. The page names the molecule correctly and never mentions that an approved product is on the market.7
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named, and no clinician either. The footer describes the arrangement as a category — a concierge telehealth platform that facilitates access to independent, US board-certified clinical providers and state-licensed compounding pharmacies — and names neither, on their site or across the whole signup. Nothing says whether the medication is made to order under a prescription or dispensed ready-made. The same disclaimer does say, plainly, that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA. Against the rest of this market that sentence is good; against this company's own corporate disclosure, which is unusually complete, the silence about the supply chain stands out.
Read on the New Wave Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere on the site or in the signup. The homepage says every formulation "is prepared by licensed U.S. compounding pharmacies" and names none. The trust signals are social and undated — a patient count, an average care rating shown as a bare figure, and testimonials on each product page. The quantified clinical claims are the trial averages placed at month six on the product pages and the week-24 chart on the homepage.
Read on the New Wave Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
New Wave Health publishes no list of states and makes no fifty-state claim. The homepage says "Telehealth in Virginia & beyond" and promises "discreet nationwide delivery", and each product page lists availability as "Telehealth · VA & beyond", without saying which states "beyond" covers. The signup never asks which state you are in; it asks for a full shipping address instead, at screen twenty-five.
Read the full licensing claim
The company is named and located: New Wave Health LLC, at 1832 Kempsville Road Suite 112, Virginia Beach, Virginia 23464, in terms last updated June 1, 2026 — with the same address given again for opting out of arbitration. That is more corporate disclosure than either of the two brands sharing this template. No clinician is named anywhere, and the published contact is a named individual's mailbox rather than a support desk.
Read on the New Wave Health site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
We did this ourselves
What happens when you sign up with New Wave Health
We went through New Wave Health’s signup ourselves in September 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- What would you like support with
- How active are you usually
- How much sleep do you normally get
- How often are you stressed
- What is your gender
- Height, current weight and goal weight
- A BMI analysis screen, with a score, an "elevated" label and a "success outlook" of 92%
- First name and last name
- Email address
- Phone number
- Which best describes your body shape
- What is your ethnicity
- A symptom checklist
- A diagnosis checklist, including thyroid cancer and endocrine neoplasia
- Have you had any surgeries or procedures
- Have you had any weight-loss surgeries
- A testimonial screen with a before-and-after photograph
- Have you ever taken a GLP-1 medication
- Do you take any medications or supplements
- Are you allergic to any of these
- Any other medication or food allergies
- What is your resting heart rate
- How disruptive would side effects be to your routine
- Your date of birth
- Your full shipping address
- A final consent screen, with a chart promising 18% of body weight lost by week 24
- No price appears at any point in the signup — not on any of its twenty-eight screens.
- The site's only figures are floors: "from $139/mo" on the homepage, which New Wave Health itself qualifies as confirmed after a provider reviews you, and a "from" figure beside each product in its peptide catalog.
- Your email is collected at screen nine, before any question about medication, allergies or diagnosis.
- Your date of birth and full shipping address are both requested before any price is shown.
- A success figure of 92% appears twice — once on the BMI screen and once on the screen headed medical review — before a clinician has seen anything.
- The final screen's chart went further than anything on the public pages: 18% of body weight by week 24.
- The published contact is a named person's mailbox rather than a support address, and it doubles as the arbitration opt-out address.
- The final screen requires confirming your answers are true, accurate and complete before the qualification button unlocks — where we stopped, because ours were not.
New Wave Health support
- Phone
- +1 757-573-0882
Assessment
What holds up, and what does not
- It names the company and its street address, in its terms and again in the footer.
- Its terms are dated, and give a postal address for opting out of arbitration.
- Its disclaimer says plainly that compounded medications are not FDA-approved and unverified by the FDA.
Show 4 more
- A published telephone number as well as an email address.
- Its product pages list who should not take each drug, including the thyroid cancer exclusion.
- Its homepage chart names the trials behind its figures and says individual outcomes vary.
- No FDA warning letter.
- Its semaglutide page puts STEP 1's 68-week average at month six, and its tirzepatide page does the same with SURMOUNT-1's 72-week result.
- The tirzepatide page adds that "many members exceed this range", with nothing published to back it.
- The homepage chart calls a 15.2% loss at week 24 a typical trial milestone.
Show 8 more
- The only prices published are floors — "from" figures, "confirmed after provider review" — beside a promise of transparent, flat-rate pricing.
- No price appeared on any of the twenty-eight signup screens, which ask for your date of birth and full shipping address.
- A 92% success figure appeared twice in the signup before any clinician had looked at anything.
- Its microdose product names no molecule and no dose anywhere.
- It sells a compounded tesamorelin, a drug that has had no lawful compounding route since it became a biologic in March 2020, and its page never mentions the HIV population the trials studied.
- Its sermorelin and PT-141 pages sell outcomes, recovery and energy for one, desire in men for the other, that their trials did not measure.
- No pharmacy is named, and nothing says whether the medication is made to order.
- No clinician is named, and the published contact is a personal mailbox rather than a support desk.
Verdict
The bottom line
Give this company credit for the part most of its rivals skip. You can find out who it is, where it is, and how to take it to arbitration. Then read its timelines with the trials beside them: the averages it quotes are real, and they took 68 and 72 weeks, not six months. And ask for a price in writing, because a floor confirmed after review is not one.
Opens New Wave Health's website. A link is not a recommendation to take anything.
It tells you who it is
Most of this market won't. New Wave Health does, in its Terms of Use, last updated 1 June 2026:
"New Wave Health LLC … owns and operates the website"
With an address — 1832 Kempsville Road Suite 112, Virginia Beach, VA 23464 — in the footer, in the terms, and again as the address you'd write to if you wanted to opt out of arbitration.
That last detail matters. A company that tells you where to send an arbitration opt-out is a company you can actually reach.
Full analysis — 4 more sectionsThen it moves the trials forward · And not what it charges · NAD+ · The rest of the peptide menu
Then it moves the trials forward
From the semaglutide page, under "Realistic timelines drawn from published clinical trials":
"MONTH 6 · ~15% · Average body weight reduction reported in published trials."
From the tirzepatide page:
"MONTH 6 · ~20% · Average body weight reduction in published trials. Many members exceed this range."
The averages are real. STEP 1 reported about 15% — after 68 weeks. 1 SURMOUNT-1's top dose reached roughly 20% — after 72 weeks. 2
Month six is about 26 weeks. Each page takes a trial's final result and puts it at roughly a third of the way through that trial. "Many members exceed this range" adds a claim about New Wave's own patients that nothing on the site backs.
The homepage chart does it from the other direction. Scrub it to the end and it reads "Week 24 · −15.2% · Typical trial milestone", under the heading "Straight from the clinical trials". Its own footnote says the trials behind it ran "roughly 24–72 weeks".
When we completed the signup in September 2026, the final screen went further still: "TYPICAL GLP-1 PROGRESS −18% body weight", at week 24.
And not what it charges
Every figure on the site is a floor. The first sits under the homepage BMI tool:
"Plans from $139/mo · confirmed after provider review"
Its peptide catalog adds a "from" figure beside each product: semaglutide injection from $139 a month, tirzepatide from $149, the microdose from $199 and an oral GLP-1 from $229. None of them is a rate you are quoted for your own plan.
The same homepage promises "transparent pricing", and both product pages promise "flat-rate pricing". Neither product page states a rate.
We completed the signup to find the real one: twenty-eight screens — goals, activity, sleep, stress, sex, height, weight, goal weight, a BMI analysis, name, email, phone, body shape, ethnicity, symptoms, diagnoses, surgeries, GLP-1 history, medications, allergies, resting heart rate, side-effect tolerance, date of birth, and a full shipping address. No dollar figure at any step.
Two screens before the end, the BMI screen showed "Your success outlook 92%", and the screen headed "Your Medical Review" showed "Success Probability 92%" and "You could reach your goal weight in about 31 weeks." No clinician had looked at anything at that point.
NAD+
New Wave also sells NAD+, and its page starts more honestly than most: "Not a peptide but a coenzyme your cells run on." What it offers is another matter. It says NAD+ "replenishes an age-depleted coenzyme" and "may support steadier day-long physical and mental energy". No completed randomized trial of injected NAD+ in people has measured either. 3 The catalog lists it from $199 a month.
The rest of the peptide menu
The same catalog sells three more peptides, each on its own page, each with a "from" floor rather than a price: tesamorelin from $299 a month, sermorelin from $249 and PT-141 from $249.
Tesamorelin is sold as "studied specifically for the deep abdominal fat that resists diet and training". The studies are real: two phase 3 trials, 675 people. 5 6 Every one of them had HIV-associated lipodystrophy, and the page never says so. It does say the product is "a compounded medication". Tesamorelin has been regulated as a biologic since March 23, 2020, and a biologic has no lawful compounding route. The only lawful tesamorelin is the brand-name drug, Egrifta.
Sermorelin is sold for "restorative rest, recovery, and the sense of vitality". Its 19 randomized trials, the newest from 2005, measured growth hormone release. None measured rest, recovery or vitality. 4
PT-141 is sold for desire "in women and men alike". Its two phase 3 trials enrolled only premenopausal women with low sexual desire. 7
Questions
Frequently asked questions
What does New Wave Health cost?
Its homepage says plans start "from $139/mo" and qualifies that itself as confirmed after a provider reviews you. Its peptide catalog lists a "from" figure beside each product — semaglutide injection from $139 a month, tirzepatide from $149. The product pages promise flat-rate pricing without stating a rate, and when we completed all twenty-eight signup screens — including date of birth and full shipping address — we were shown no figure at any point.
Will I lose 15% by month six on semaglutide, or 20% on tirzepatide?
Not on the published record. Those are the trials' averages, but STEP 1 reported about 15% after 68 weeks of semaglutide, and SURMOUNT-1's top dose reached roughly 20% after 72 weeks. New Wave Health's product pages put both figures at month six — about a third of the way through each trial.
Who is New Wave Health?
New Wave Health LLC, at 1832 Kempsville Road Suite 112 in Virginia Beach, Virginia, named in terms dated June 1, 2026. It's the most complete corporate disclosure of the three brands running this template, and it's a genuine point in the company's favor.
What is the 92% success probability?
A figure the site generates from your height, weight and goal weight, shown on two screens before any clinician has seen anything. No trial reports a success probability for an individual — published results are averages with a spread around them, including people who didn't respond.
Who makes the medication?
New Wave Health doesn't say. Its disclaimer describes state-licensed compounding pharmacies as a category and names none, and nothing says whether your medication is made to order under a prescription or dispensed ready-made. No clinician is named either.
Can a pharmacy compound the tesamorelin New Wave Health sells?
Not lawfully. Tesamorelin has been regulated as a biologic since March 23, 2020, and biologics sit outside both compounding routes. The approved product is Egrifta, for excess abdominal fat in adults with HIV. New Wave Health's page calls its tesamorelin "a compounded medication" and does not mention HIV.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what New Wave Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists New Wave Health is on
- Best Peptide Providers by Claim Accuracy
- Semaglutide Sellers, Ranked by Claim Accuracy
- Tirzepatide Sellers, Ranked by Claim Accuracy
- Sermorelin Sellers and What the Trials Show
- NAD+ Sellers and What the Trials Show
- PT-141 Sellers and What the Trials Show
- Peptides for Women: Sellers and the Evidence
- Peptides for Men: Sellers and the Evidence
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off New Wave Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 7 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, roughly 20% mean reduction at the top dose reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.